Advertisement

Alector, Inc. ALEC

Set alert

Price alert · ALEC

All alert types
2.21 USD -0.03 -1.34%

At close

2.16 -0.05 -2.26%

Pre-market · Nov 2, 8:44 AM ET

Bid
2.19 × 2
Ask
2.20 × 2
2.09 Day range 2.25
1.09 52-week range 2.76
YTD
+41.67%
1 year
+45.39%
Open
2.20
Prev close
2.24
Mkt cap
246.76M
Vol
1.11M
Avg vol
3.33M
EPS
-1.09
P/E
0.00
Div yield
0.00%
More statistics
Low
2.09
High
2.25
Forward P/E
-1.25
Beta
0.66
Short ratio
3.92
Inst. own
95.87%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
3.81
200-d avg
4.92
1y target
5.51

2Y chart

Chart tools
Interval

Events in this range
  • Nov 6, 2024Earnings: -0.43; estimate -0.53; surprise 18.87%
  • Nov 7, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Nov 26, 2024Rating: Cantor Fitzgerald · — → Overweight
  • Nov 26, 2024Rating: BTIG · Buy → Buy
  • Nov 26, 2024Downgrade: Morgan Stanley · Equal-Weight → Underweight
  • Dec 16, 2024Downgrade: Stifel · Buy → Hold
Signals (81)
NameDateAgo
SMA: BullishOct 27, 20266 days ago
SMA: BullishOct 27, 20266 days ago
MACD: Buy SignalOct 27, 20266 days ago
MACD: Sell SignalOct 22, 20261 week ago
SMA: BearishOct 13, 20262 weeks ago
SMA: BearishOct 13, 20262 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BullishOct 8, 20263 weeks ago
MACD: Buy SignalOct 8, 20263 weeks ago
SMA: BearishSep 24, 20261 month ago
SMA: BearishSep 24, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 16, 20261 month ago
SMA: BearishSep 16, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
RSI: OverboughtAug 19, 20262 months ago
SMA: BullishAug 11, 20262 months ago
SMA: BullishAug 6, 20262 months ago
MACD: Buy SignalJul 28, 20263 months ago
RSI: OversoldJul 14, 20263 months ago
MACD: Sell SignalJul 10, 20263 months ago
SMA: BearishJul 6, 20263 months ago
SMA: BearishJul 6, 20263 months ago
SMA: BullishJul 2, 20264 months ago
SMA: BullishJul 2, 20264 months ago
SMA: BearishJun 30, 20264 months ago
SMA: BullishJun 29, 20264 months ago
MACD: Buy SignalJun 22, 20264 months ago
RSI: OversoldJun 5, 20265 months ago
RSI: OversoldJun 3, 20265 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BullishMay 12, 20265 months ago
SMA: BearishMay 11, 20265 months ago
SMA: BearishMay 8, 20265 months ago
MACD: Sell SignalMay 7, 20265 months ago
MACD: Buy SignalMay 6, 20266 months ago
MACD: Sell SignalApr 23, 20266 months ago
MACD: Buy SignalApr 1, 20267 months ago
SMA: BullishMar 31, 20267 months ago
SMA: BearishMar 27, 20267 months ago
MACD: Sell SignalMar 5, 20268 months ago
RSI: OverboughtFeb 24, 20268 months ago
MACD: Buy SignalFeb 23, 20268 months ago
MACD: Sell SignalJan 29, 20269 months ago
RSI: OverboughtJan 27, 20269 months ago
RSI: OverboughtJan 23, 20269 months ago
SMA: BullishJan 7, 20269 months ago
RSI: OverboughtJan 7, 20269 months ago
SMA: BullishDec 29, 202510 months ago
RSI: OversoldNov 19, 202511 months ago
MACD: Buy SignalNov 13, 202511 months ago
SMA: BearishOct 22, 20251 year ago
SMA: BearishOct 22, 20251 year ago
RSI: OversoldOct 22, 20251 year ago
MACD: Sell SignalSep 25, 20251 year ago
MACD: Buy SignalSep 18, 20251 year ago
MACD: Sell SignalSep 16, 20251 year ago
RSI: OverboughtSep 3, 20251 year ago
RSI: OverboughtAug 14, 20251 year ago
RSI: OverboughtAug 11, 20251 year ago
SMA: BullishAug 8, 20251 year ago
MACD: Buy SignalAug 8, 20251 year ago
SMA: BearishAug 6, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BearishJul 31, 20251 year ago
MACD: Sell SignalJul 30, 20251 year ago
MACD: Buy SignalJul 9, 20251 year ago
MACD: Sell SignalJun 18, 20251 year ago
SMA: BullishMay 16, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BullishMay 2, 20251 year ago
MACD: Buy SignalApr 15, 20251 year ago
RSI: OversoldApr 3, 20251 year ago
MACD: Sell SignalApr 1, 20251 year ago
MACD: Buy SignalMar 27, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
RSI: OversoldMar 3, 20251 year ago
SMA: BearishFeb 24, 20251 year ago
RSI: OversoldJan 14, 20251 year ago
RSI: OversoldNov 26, 20241 year ago

Key statistics

Market cap
181.18M
Enterprise value
-240.41M
Trailing P/E
0.00
Forward P/E
-1.25
PEG ratio
0.00
Price / sales
2.95
Price / book
1.52
EPS (TTM)
-1.71
Beta
0.66
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-257.54%
Revenue (TTM)
61.51M
Revenue growth
68.40%
Free cash flow
-66.92M
Total cash
457.20M
Total debt
34.64M
Return on equity
-112.55%
Shares outstanding
97.93M
Short % of float
7.83%
50-day average
3.81
200-day average
4.92

Analyst view

Consensus: buy

Buy
Price target (mean) 5.51 +149.4% upside
Target (low)
1.00
Target (mean)
5.51
Target (high)
12.00
Ratings (0m) 10 7 buy · 1 hold · 2 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell1
  • Strong sell1

Next earnings

Aug 7, 2024

Expected Aug 7, 2024. Consensus EPS estimate -0.53686.

Earnings history

Financials — quick view

All financials
ALEC Revenue — quarterly 3.32M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALEC Net income — quarterly -22.99M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ALEC EPS — quarterly -0.21
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ALEC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.53-0.43+0.10+18.87%
Aug 7, 2024Jun 1, 2024-0.49-0.40+0.09+18.37%
Aug 7, 2024Jun 1, 2024-0.49———
May 8, 2024Mar 1, 2024-0.48-0.38+0.10+20.83%
May 8, 2024Mar 1, 2024-0.48———
Feb 27, 2024Dec 1, 2023-0.80-0.49+0.31+38.75%

Upgrades / downgrades

ALEC analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024StifeldownBuyHold
Nov 26, 2024Morgan StanleydownEqual-WeightUnderweight
Nov 26, 2024BTIGmainBuyBuy
Nov 26, 2024Cantor Fitzgeraldreit—Overweight
Nov 7, 2024HC Wainwright & Co.reitBuyBuy
Sep 17, 2024Cantor Fitzgeraldreit—Overweight

About Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
alector.com

News

Your note

Sign in to keep a note on ALEC — it syncs with the Stock Master app.

Insider holders

ALEC insider holders
InsiderRelationLatest transactionDateShares held
GAROFALO ELIZABETH A.DirectorStock Award(Grant)Jun 11, 202461,250
GRASSO MARCChief Financial OfficerSaleDec 1, 2024330,651
HAMMOND PAULADirectorSaleAug 11, 202460,209
KENKARE-MITRA SARASWATIOfficerSaleDec 1, 2024565,215
LAVIGNE LOUIS J JRDirectorStock Award(Grant)Jun 11, 202481,261
ROMANO GARYOfficerSaleDec 1, 2024349,283

Institution ownership

ALEC institution ownership
Holder% heldSharesValueReported
FMR, LLC14.90%14,595,01427.00MSep 29, 2024
Blackrock Inc.9.55%9,352,04417.30MSep 29, 2024
Vanguard Group Inc5.57%5,455,72710.09MSep 29, 2024
Deep Track Capital, Lp4.73%4,631,9988.57MSep 29, 2024
Morgan Stanley4.45%4,355,7708.06MSep 29, 2024
JP Morgan Chase & Company2.79%2,728,8235.05MSep 29, 2024

Fund ownership

ALEC fund ownership
Holder% heldSharesValueReported
Fidelity Growth Company Fund3.71%3,637,3696.73MOct 30, 2024
Fidelity Select Portfolios - Biotechnology3.61%3,535,7536.54MOct 30, 2024
Vanguard Total Stock Market Index Fund2.42%2,365,5714.38MSep 29, 2024
iShares Russell 2000 ETF2.14%2,098,3413.88MOct 30, 2024
JP Morgan Small Cap Growth Fund1.54%1,506,6112.79MSep 29, 2024
Fidelity Growth Company K6 Fund1.30%1,268,9312.35MOct 30, 2024
Advertisement